|
| Press Releases |
|
 |
|
| Monday, November 7, 2022 |
|
|
エーザイ、筋緊張改善剤「ミオナール(R)」、めまい・平衡障害治療剤「メリスロン(R)」についてアジアにおける権利をDKSHに譲渡 |
| エーザイ株式会社は、このたび、筋緊張改善剤「ミオナール(R)」（一般名：エペリゾン塩酸塩）、および めまい・平衡障害治療剤「メリスロン(R)」（一般名：ベタヒスチンメシル酸塩）について、アジア（９カ国・地域*）における権利を DKSH Holding Ltd.の子会社に譲渡する契約を締結したことをお知らせします。 more info >> |
|
| Friday, November 4, 2022 |
|
|
エーザイ、タイにおいてThai Life Insuranceとアルツハイマー病をはじめとする認知症の治療に対するアクセス支援に向けた協働について合意 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、当社のタイ販売子会社である Eisai（Thailand）Marketing Co., Ltd., （以下 エーザイ・タイランド）がタイの大手生命保険会社である Thai Life Insurance Public Company Limited（本社：タイ バンコク、Director & CEO：Chai Chaiyawan、以下 Thai Life Insurance）と、タイにおけるアルツハイマー病をはじめとする認知症の治療に対するアクセス支援に向け協働することに合意したことをお知らせします。 more info >> |
|
|
Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer's Disease, in Thailand |
| Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co. Ltd. ("Eisai Thailand") made an agreement to collaborate in supporting access to treatments for dementia, including Alzheimer's disease, in Thailand with Thai Life Insurance Public Company Limited, a leading life insurance company in Thailand. more info >> |
|
| Wednesday, November 2, 2022 |
|
|
Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon |
| Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case study" specified post-marketing observational study condition. more info >> |
|
|
Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination |
| Eisai Co., Ltd. announced today that it has received notification that Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies that was discovered and developed in-house, has been granted Category 2* status based on the results of a reexamination of its efficacy, dosage and administration for the treatment of dementia with Lewy bodies (DLB) in Japan. more info >> |
|
| Monday, October 31, 2022 |
|
|
エーザイ、「アリセプト(R)」について日本のレビー小体型認知症に係る適応に関する再審査結果に伴う用法・用量の一部変更申請の予定について発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、本日、自社創製のアルツハイマー型認知症・レビー小体型認知症治療剤「アリセプト(R)」（一般名：ドネペジル塩酸塩）について、日本におけるレビー小体型認知症（DLB）に係る効能・効果および用法・用量に関する再審査の結果、カテゴリー2*となった旨の通知を受領しました。 more info >> |
|
| Tuesday, October 4, 2022 |
|
|
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan |
| Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan "EWAY Future & Beyond", it has completed construction of the new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
|
エーザイ、川島工園において新注射剤棟/研究棟が竣工 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、当社の中期経営計画 EWAY Future & Beyond における戦略投資の一環として、川島工園（岐阜県）において建設中であった新注射剤棟/研究棟（名称：Eisai Medicine Innovation Technology Solutions、以下 EMITS）が竣工したことをお知らせします。 more info >> |
|
| Wednesday, September 28, 2022 |
|
|
Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint |
| Eisai Co., Ltd. and Biogen Inc. announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab. more info >> |
|
|
エーザイ、レカネマブがグローバル大規模臨床第III相CLARITY AD検証試験で統計学的に高度に有意な臨床症状の悪化抑制を示し、主要評価項目を達成 |
| エーザイ、「レカネマブ」についてグローバル大規模臨床第III相CLARITY AD検証試験にて統計学的に高度に有意な臨床症状の悪化抑制を示し、主要評価項目を達成 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TANAKA PRECIOUS METAL TECHNOLOGIES, 5세대 신호 릴레이용 차세대 접점 ‘극소형 크로스바 접점’ 개발
Mar 12, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES開發出適用於第5代訊號繼電器的次世代接點「極小CROSS BAR接點（帶狀接點）」
Mar 12, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES已开发了面向第5代信号继电器的次世代接点 “微小CROSS BAR接点（异型材带状接点）”
Mar 12, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Develops Miniaturized Micro Profile, a Next-Generation Contact tape for Fifth-Generation Signal Relays
Mar 12, 2025 11:00 JST
|
|
|
JCB Now Available on Google Play in Thailand, Indonesia, Vietnam, Philippines, and Hong Kong
Mar 12, 2025 11:00 JST
|
|
|
Bear Robotics「Carti 100」榮獲 2025 年 iF 設計大獎，引領物流自動化新標準
Mar 11, 2025 23:58 HKT/SGT
|
|
|
Bear Robotics' Carti 100 Wins iF DESIGN AWARD 2025, Setting New Standards in Logistics Automation
Mar 11, 2025 23:58 HKT/SGT
|
|
|
Formerra Introduces Formerra+ Upgraded Ecommerce Site to Optimize Customer Experience
Mar 11, 2025 22:15 HKT/SGT
|
|
|
135 Years of Sport Inspiration: U.S. Polo Assn. Hosts Celebration Cup Exhibition and Spring-Summer 2025 Fashion Showcase in Delhi
Mar 11, 2025 20:00 HKT/SGT
|
|
|
聯想控股旗下君聯資本、正奇能科集團共同投資企業漢朔科技在深交所成功上市
Mar 11, 2025 19:00 HKT/SGT
|
|
|
联想控股旗下君联资本、正奇能科集团共同投资企业汉朔科技在深交所成功上市
Mar 11, 2025 18:52 HKT/SGT
|
|
|
2024 Results of Qunabox Group Released: Leading AI Interactive Marketing with Strong Revenue and Profit Growth
Mar 11, 2025 18:50: JST
|
|
|
2024 Results of Qunabox Group Released: Leading AI Interactive Marketing with Strong Revenue and Profit Growth
Mar 11, 2025 17:50 HKT/SGT
|
|
|
JCB Announced Premier Sponsorship for the 10th Edition of Sakura 2025 at Singapore's Gardens by the Bay
Mar 11, 2025 18:00 JST
|
|
|
Hitachi Energy invests additional $250 million USD to address global transformer shortage
Mar 11, 2025 17:49 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
